Cargando…

Meta-analysis of phase III trials of docetaxel alone or in combination with chemotherapy in metastatic breast cancer

PURPOSE: Whether combination chemotherapy offers an advantage over sequential therapy in metastatic breast cancer (MBC) is still an unsettled issue. Polychemotherapy regimens containing taxanes has been shown to increase overall survival (OS), time to tumor progression (TTP), and overall response ra...

Descripción completa

Detalles Bibliográficos
Autores principales:	Belfiglio, Maurizio, Fanizza, Caterina, Tinari, Nicola, Ficorella, Corrado, Iacobelli, Stefano, Natoli, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2011
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3258394/ https://www.ncbi.nlm.nih.gov/pubmed/22095437 http://dx.doi.org/10.1007/s00432-011-1091-0

Ejemplares similares

Breast cancer follow-up strategies in randomized phase III adjuvant clinical trials: a systematic review
por: Sperduti, Isabella, et al.
Publicado: (2013)

Circulating Autoantibodies to LGALS3BP: A Novel Biomarker for Cancer
por: Grassadonia, Antonino, et al.
Publicado: (2013)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Timed flat infusion of 5-fluorouracil increases the tolerability of 5-fluorouracil/docetaxel regimen in metastatic breast cancer: a dose-finding study
por: Ficorella, C, et al.
Publicado: (2004)

Impact of primary tumor location in patients with RAS wild-type metastatic colon cancer treated with first-line chemotherapy plus anti-EGFR or anti-VEGF monoclonal antibodies: a retrospective multicenter study
por: Grassadonia, Antonino, et al.
Publicado: (2019)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Phase I study of docetaxel in combination with cyclophosphamide as first-line chemotherapy for metastatic breast cancer
por: Vasey, P A, et al.
Publicado: (2002)

Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2)
por: Rosenberg, Jonathan E., et al.
Publicado: (2018)

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209
por: Eigl, Bernhard Josef, et al.
Publicado: (2018)

Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer
por: Takayama, T, et al.
Publicado: (2007)

Breast Cancer “Tailored Follow-up” in Italian Oncology Units: A Web-Based Survey
por: Natoli, Clara, et al.
Publicado: (2014)

Docetaxel, Cisplatin, and 5‐Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma
por: Fiteni, Frédéric, et al.
Publicado: (2016)

Immunological effects of alternative weekly interferon-alpha-2b and low dose interleukin-2 in patients with cancer.
por: Fiorentino, B., et al.
Publicado: (1992)

Prognostic value of a novel circulating serum 90K antigen in breast cancer.
por: Iacobelli, S., et al.
Publicado: (1994)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

A randomized phase III study of docetaxel alone versus docetaxel plus S‐1 in patients with previously treated non‐small cell lung cancer: JMTO LC09‐01
por: Atagi, Shinji, et al.
Publicado: (2023)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer
por: Pallis, Athanasios G, et al.
Publicado: (2010)

A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma
por: Bramwell, Vivien, et al.
Publicado: (1998)

Phase II study of docetaxel, cisplatin, and fluorouracil in patients with distantly metastatic penile cancer as first-line chemotherapy
por: Zhang, Sheng, et al.
Publicado: (2015)

Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial
por: Ellis, Paul, et al.
Publicado: (2009)

Phase II feasibility study of adjuvant chemotherapy with docetaxel/cisplatin/S-1 followed by S-1 for stage III gastric cancer
por: Hirahara, Noriyuki, et al.
Publicado: (2021)

The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
por: Wang, Tian, et al.
Publicado: (2022)

Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma
por: Peng, Pei-Jian, et al.
Publicado: (2015)

Class III β-tubulin expression as a predictor of docetaxel-resistance in metastatic castration-resistant prostate cancer
por: Maahs, Lucas, et al.
Publicado: (2019)

EGFR amplification and outcome in a randomised phase III trial of chemotherapy alone or chemotherapy plus panitumumab for advanced gastro-oesophageal cancers
por: Smyth, Elizabeth C, et al.
Publicado: (2021)

Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials
por: Grassadonia, Antonino, et al.
Publicado: (2018)

Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients
por: Bruera, Gemma, et al.
Publicado: (2013)

Dynamic test with recombinant interferon-alpha-2b: effect on 90K and other tumour-associated antigens in cancer patients without evidence of disease.
por: Natoli, C., et al.
Publicado: (1993)

Randomized phase II study with two gemcitabine- and docetaxel-based combinations as first-line chemotherapy for metastatic non-small cell lung cancer
por: Passardi, Alessandro, et al.
Publicado: (2008)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
por: Unger, Joseph M., et al.
Publicado: (2018)

Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide
por: Young, R J, et al.
Publicado: (2012)

Multimodality Treatment in Metastatic Gastric Cancer: From Past to Next Future
por: Parisi, Alessandro, et al.
Publicado: (2020)

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients.
por: de Wit, R., et al.
Publicado: (1998)

Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001)
por: Nicholson, S, et al.
Publicado: (2013)

The Combination of Omega-3 Stearidonic Acid and Docetaxel Enhances Cell Death over Docetaxel Alone in Human Prostate Cancer Cells
por: Mansour, Mahmoud, et al.
Publicado: (2018)

Phase I/II study of S-1 combined with weekly docetaxel in patients with metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2008)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

Phase II study of epirubicin, oxaliplatin and docetaxel combination in metastatic gastric or gastroesophageal junction adenocarcinoma
por: Di Lauro, Luigi, et al.
Publicado: (2009)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_pa47u5292l02u2vvsq7mspn200